Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825598 | 0.96 | F7 (0.40) | CYP1A2CYP2C9CYP2C19HTTF7 | |
| SCHEMBL8717261 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTF7 | |
| SCHEMBL6822145 | 0.81 | CTSK (0.42) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL14364462 | 0.77 | DPP4 (0.41) | CA1CA2SMN1; SMN2 | |
| SCHEMBL8221898 | 0.77 | DPP4 (0.41) | CA1CA2SMN1; SMN2 | |
| SCHEMBL5532294 | 0.73 | CTSK (0.42) | CTSKCTSSKMT2ACTSLCA1 | |
| SCHEMBL5532292 | 0.73 | CTSK (0.42) | CTSKCTSSKMT2ACTSLCA1 | |
| SCHEMBL5527345 | 0.72 | CTSK (0.42) | CTSKCTSSKMT2ACTSLCA1 | |
| SCHEMBL4665948 | 0.72 | CTSK (0.42) | CTSKCTSSKMT2ACTSLCA1 | |
| SCHEMBL21974625 | 0.71 | CYP1A2 (0.52) | CYP1A2CYP2C9CYP2C19HTTCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| WO-2007121125-A2 | HCV INHIBITORS | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265281-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CYP1A2 111/4885CYP2C9 228/4885CYP2C19 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.